COVINA, Calif., Dec. 13, 2011 /PRNewswire/ -- Renowned experts in cord blood collection, processing and transplantation have joined StemCyte, Inc. The added resources are evidence of its commitment as a worldwide industry leader in developing and providing the safest and most effective cord blood therapies for treating patients.
Dr. Wise Young MD PhD has agreed to join StemCyte as its Global Medical Director. He will serve in a voluntary (unpaid) and part-time capacity to help StemCyte organize its medical and research programs based on his firm belief in StemCyte as the best company today delivering cord blood stem cell units for life-saving therapies. Professor Young is the founding Director of the W. M. Keck Center for Collaborative Neuroscience and helped found the New Jersey Stem Cell Research Center at Rutgers, the State University of New Jersey. He has been voluntarily advising StemCyte since 2003 on its research and development programs. He is currently conducting clinical trials to assess the safety and efficacy of human UCB cells and lithium treatment of chronic and acute spinal cord injury using StemCyte cord blood units. Prof. Young will help StemCyte develop stem cell therapies for new conditions such as spinal cord injury, stroke, and genetic disorders. He will work with the team at StemCyte to develop the highest quality standards at its facilities and to organize collaborations with scientists worldwide to develop cutting-edge therapies with UCB and other stem cells.
"Wise is a unique and incredibly talented individual that I have been privileged to know and work with for the past 16 years," said Chairman and CEO, Ken Giacin. "StemCyte is fortunate to have the benefit of his scientific expertise, dedication to our mission and passion for developing new promising therapies using high quality cells from cord blood."
In addition, StemCyte Inc. has recruited t
|SOURCE StemCyte, Inc.|
Copyright©2010 PR Newswire.
All rights reserved